ArticleFrontiers in oncology2025
Multiline treatment of primary cutaneous adenoid cystic carcinoma with multiple metastases: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features.Frontiers in medicine · 2026Article
- Primary cutaneous adenoid cystic carcinoma arising in the axilla: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary cutaneous adenoid cystic carcinoma (PCACC) is an extremely rare malignancy, typically presenting as a slow-growing, painless cutaneous mass with a relatively favorable prognosis compared to adenoid cystic carcinomas (ACC) of salivary gland origin. Metastatic PCACC is uncommon, with stage IV disease accounting for approximately 4% of reported cases. Due to its rarity, clinical understanding of the disease course and optimal management strategies remains limited. Case presentation: We report the case of a 57-year-old male who presented with a painful ulcerated mass on the left ankle. Magnetic resonance imaging (MRI) revealed a subcutaneous lesion, and histopathological examination following surgical excision confirmed the diagnosis of ACC. Immunohistochemistry was consistent with ACC, and a PET-CT scan excluded regional or distant disease, supporting the diagnosis of PCACC. The patient subsequently underwent adjuvant radiotherapy. However, within eight months, follow-up imaging revealed pulmonary and osseous metastases. A biopsy confirmed metastatic ACC consistent with the primary lesion. The patient was treated sequentially with three lines of systemic therapy, including chemotherapy, immunotherapy, and targeted therapy, along with palliative radiotherapy. Despite temporary disease stabilization, the malignancy progressed rapidly, with new pulmonary, intracranial, and extensive skeletal metastases. The patient eventually discontinued treatment and was lost to follow-up. Conclusion: This case highlights an unusually aggressive clinical course of PCACC with rapid progression to widespread metastatic disease shortly after definitive local treatment. Given the rarity of metastatic PCACC, this report contributes valuable insight into its natural history, diagnostic approach, and therapeutic challenges. It underscores the need for heightened clinical awareness and further research into effective systemic treatment strategies for advanced PCACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.